Invega
NDC Package 64725-0550-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Invega is a medication used to treat certain mental/mood disorders (such as schizophrenia, schizoaffective disorder). Marketed by Tya Pharmaceuticals, this product is identified by NDC 64725-0550 and is authorized under FDA application NDA021999.

Identification & Billing

NDC Package Code
64725-0550-1
Package Description
30 TABLET, EXTENDED RELEASE in 1 BOTTLE
Product Code
64725-0550
11-Digit Billing Format
64725055001
RxNorm Crosswalk
  • RxCUI: 672567 - paliperidone 3 MG 24HR Extended Release Oral Tablet
  • RxCUI: 672567 - 24 HR paliperidone 3 MG Extended Release Oral Tablet
  • RxCUI: 672567 - paliperidone 3 MG 24 HR Extended Release Oral Tablet
  • RxCUI: 686441 - INVEGA 3 MG 24HR Extended Release Oral Tablet
  • RxCUI: 686441 - 24 HR paliperidone 3 MG Extended Release Oral Tablet [Invega]

Clinical Specifications

Proprietary Name
Invega
Dosage Form
-
Usage Information
This medication is used to treat certain mental/mood disorders (such as schizophrenia, schizoaffective disorder). This medication can decrease hallucinations and help you to think more clearly and positively about yourself, feel less agitated, and take a more active part in everyday life. Paliperidone belongs to a class of drugs called atypical antipsychotics. It works by helping to restore the balance of certain natural substances in the brain.

Regulatory & Marketing

Labeler Name
Tya Pharmaceuticals
FDA Application #
NDA021999
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
12-19-2006
Listing Expiration
12-31-2017
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 64725-0550-1 identifies a specific commercial package of 30 tablet, extended release in 1 bottle of Invega, labeled by Tya Pharmaceuticals. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Tya Pharmaceuticals on December 19, 2006. The current certification is valid through December 31, 2017.

What are the primary indications for this medication?

This medication is used to treat certain mental/mood disorders (such as schizophrenia, schizoaffective disorder). This medication can decrease hallucinations and help you to think more clearly and positively about yourself, feel less agitated, and take a more active part in everyday life. Paliperidone belongs to a class of drugs called atypical antipsychotics. It works by helping to restore the balance of certain natural substances in the brain.

How is this Tya Pharmaceuticals product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 64725055001. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
64725-0550-1
11-Digit CMS (5-4-2)
64725-0550-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.